Screener
Mesa Laboratories MLAB Biopharmaceutical Development — Cost Of Goods And Services Sold Depreciation
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSoldDepreciation.
The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026808
| Three months ended June 30, 2026 | Sterilization and Disinfection Control | Biopharmaceutical Development | Calibration Solutions | Clinical Genomics | Total |
|---|---|---|---|---|---|
| Revenue (a): | $24,505 | $12,059 | $13,285 | $10,289 | $60,138 |
| Less | |||||
| Depreciation in cost of revenue | 437 | 78 | 111 | 119 | 745 |
| Amortization in cost of revenue | 121 | 379 | - | 191 | 691 |
| Other cost of revenue (b) | 6,788 | 4,020 | 5,143 | 3,739 | 19,690 |
| Total segment cost of revenue | 7,346 | 4,477 | 5,254 | 4,049 | 21,126 |
| Gross Profit (c) | $17,159 | $7,582 | $8,031 | $6,240 | $39,012 |
| Reconciling items: |
Document
FAQ
- What is Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation?
- Mesa Laboratories (MLAB) reported biopharmaceutical development — cost of goods and services sold depreciation of $78K in Q2 2026.
- How has Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation changed year-over-year?
- Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation decreased by 12.4% year-over-year, from $89K to $78K.
- What is the long-term trend for Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation?
- Over 2 years (2024 to 2026), Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation has grown at a 17.3% compound annual growth rate (CAGR), from $224K to $308K.
- What does biopharmaceutical development — cost of goods and services sold depreciation mean?
- Captures the portion of depreciation expense allocated to the cost of goods sold for the Biopharmaceutical Development segment. This represents the systematic allocation of the cost of tangible assets used in the manufacturing or service delivery process. It is a key component in understanding the capital intensity of the segment's production operations.
Ask your AI about Mesa Laboratories's biopharmaceutical development — cost of goods and services sold depreciation.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude